ENSC Ensysce Biosciences, Inc.: רווח נקי למניה ב-12 החודשים האחרונים

Ensysce Biosciences (ENSC) is accelerating formula discovery through the automation of laboratory tests. This annual EPS TTM chart illustrates the rate of change in earnings per share, where 27.60 determines the current status of the parameter. TAAP and MPAR technologies create a closed patent environment, locking clinics into the company's protocols, while development relies on academic alliances without mergers.

This indicator calculates the percentage change in net income per share over the last twelve months relative to the same period last year. This metric determines the rate of capital generation and the fundamental resilience of the business to market volatility. For Ensysce Biosciences (ENSC), such dynamics reflect the commercialization efficiency of the TAAP and MPAR platforms in combating the opioid crisis. Investors should evaluate the annual EPS TTM delta as an indicator of the scalability of the company's innovative technologies. Negative trends in the annual EPS TTM delta may signal high R&D expenditures.